- Home
- PRPO vs CYCN Comparison
PRPO vs CYCN Comparison
Compare PRPO & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPO
- CYCN
- Stock Information
- Founded
- PRPO N/A
- CYCN 2018
- Country
- PRPO United States
- CYCN United States
- Employees
- PRPO 57
- CYCN N/A
- Industry
- PRPO Biotechnology: Laboratory Analytical Instruments
- CYCN Biotechnology: Pharmaceutical Preparations
- Sector
- PRPO Industrials
- CYCN Health Care
- Exchange
- PRPO Nasdaq
- CYCN Nasdaq
- Market Cap
- PRPO 9.5M
- CYCN N/A
- IPO Year
- PRPO N/A
- CYCN N/A
- Fundamental
- Price
- PRPO $6.59
- CYCN $2.81
- Analyst Decision
- PRPO
- CYCN
- Analyst Count
- PRPO 0
- CYCN 0
- Target Price
- PRPO N/A
- CYCN N/A
- AVG Volume (30 Days)
- PRPO 7.9K
- CYCN 9.8K
- Earning Date
- PRPO 11-11-2024
- CYCN 11-11-2024
- Dividend Yield
- PRPO N/A
- CYCN N/A
- EPS Growth
- PRPO N/A
- CYCN N/A
- EPS
- PRPO N/A
- CYCN 1.22
- Revenue
- PRPO $16,719,999.00
- CYCN N/A
- Revenue This Year
- PRPO $75.18
- CYCN N/A
- Revenue Next Year
- PRPO N/A
- CYCN N/A
- P/E Ratio
- PRPO N/A
- CYCN $2.43
- Revenue Growth
- PRPO 52.61
- CYCN N/A
- 52 Week Low
- PRPO $4.31
- CYCN $1.75
- 52 Week High
- PRPO $8.99
- CYCN $5.25
- Technical
- Relative Strength Index (RSI)
- PRPO 52.82
- CYCN 60.71
- Support Level
- PRPO $6.42
- CYCN $2.29
- Resistance Level
- PRPO $6.99
- CYCN $2.91
- Average True Range (ATR)
- PRPO 0.33
- CYCN 0.29
- MACD
- PRPO -0.04
- CYCN 0.05
- Stochastic Oscillator
- PRPO 69.91
- CYCN 109.37
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.